Tokyo Tape
Sign in
← Nipro

Quarterly report · Q2

8086.TEDINET S100S9GB
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥285.9bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥545.2bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥260.3bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥13.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥6.4bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥14.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥15.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥17.5bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥13.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥9.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥10.4bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥7.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.10Tat 2023-09-30Cons.Assets
Total assets¥1.03Tat 2023-03-31Cons.Assets
Total assets¥1.01Tat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥821.8bnat 2023-09-30Cons.Liabilities
Total liabilities¥785.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥274.0bnat 2023-09-30Cons.Net assets
Net assets / equity¥242.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥237.2bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥87.2bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥89.7bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥83.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥84.7bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥89.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.1bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥18.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥10.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥35.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥71.7bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥41.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥8.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥43.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥23.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥60.892023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥35.762023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.052022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥5.992022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥53.952023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥24.852022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥33.972022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio21.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio20.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio22.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥2.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥417m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥109m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥36.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥14.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥223.6bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥220.2bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥22.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥62.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥35.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥27.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.7bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2023-04-01 → 2023-09-30¥33.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.4bn
—segment totalrevenue2023-04-01 → 2023-09-30¥319.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥285.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥34.0bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥27.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥321.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥285.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥36.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥27.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥2.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥340m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥168m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥15.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥203.9bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥200.8bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥44.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥34.1bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10.8bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥849m
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-09-30¥28.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-09-30¥25.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
—segment totalrevenue2022-04-01 → 2022-09-30¥276.8bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥260.0bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥16.8bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥21.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥278.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥260.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥18.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥21.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 644
ItemContextValueUnit
Provision for directors retirement benefitsCurrentQuarterInstant513000000JPY
Provision for share based remuneration for directors and other officers nclPrior1YearInstant11000000JPY
Provision for share based remuneration for directors and other officers nclCurrentQuarterInstant10000000JPY
Provision for loss on litigation nclPrior1YearInstant153000000JPY
Provision for loss on litigation nclCurrentQuarterInstant210000000JPY
Other nclPrior1YearInstant26291000000JPY
Other nclCurrentQuarterInstant24473000000JPY
Noncurrent liabilitiesPrior1YearInstant482315000000JPY
Noncurrent liabilitiesCurrentQuarterInstant473855000000JPY
LiabilitiesPrior1YearInstant785225000000JPY
LiabilitiesCurrentQuarterInstant821756000000JPY
Capital stockPrior1YearInstant84397000000JPY
Capital stockCurrentQuarterInstant84397000000JPY
Retained earningsPrior1YearInstant95521000000JPY
Retained earningsCurrentQuarterInstant103965000000JPY
Treasury stockPrior1YearInstant-10748000000JPY
Treasury stockCurrentQuarterInstant-10749000000JPY
Shareholders equityPrior1YearInstant169170000000JPY
Shareholders equityCurrentQuarterInstant177614000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant7162000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant5828000000JPY
Deferred gains or losses on hedgesPrior1YearInstant-47000000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-47000000JPY
Foreign currency translation adjustmentPrior1YearInstant28716000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant52514000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1315000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1196000000JPY
Valuation and translation adjustmentsPrior1YearInstant37147000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant59491000000JPY
Non controlling interestsPrior1YearInstant35856000000JPY
Non controlling interestsCurrentQuarterInstant36866000000JPY
Net assetsPrior1YearInstant242173000000JPY
Net assetsCurrentQuarterInstant273972000000JPY
Liabilities and net assetsPrior1YearInstant1027399000000JPY
Liabilities and net assetsCurrentQuarterInstant1095729000000JPY
Net salesPrior1YTDDuration260339000000JPY
Net salesCurrentYTDDuration285865000000JPY
Cost of salesPrior1YTDDuration181475000000JPY
Cost of salesCurrentYTDDuration200062000000JPY
Gross profitPrior1YTDDuration78863000000JPY
Gross profitCurrentYTDDuration85803000000JPY
Selling general and administrative expensesPrior1YTDDuration72492000000JPY
Selling general and administrative expensesCurrentYTDDuration72315000000JPY
Operating incomePrior1YTDDuration6371000000JPY
Operating incomeCurrentYTDDuration13488000000JPY
Interest income noiPrior1YTDDuration484000000JPY
Interest income noiCurrentYTDDuration679000000JPY
Dividends income noiPrior1YTDDuration770000000JPY
Dividends income noiCurrentYTDDuration518000000JPY
Foreign exchange gains noiPrior1YTDDuration6543000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass